Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

Rezolute Inc. (NASDAQ:RZLT) is one of the top long-term biotechnology stocks to buy. Wedbush analyst Yun Zhong reaffirmed a Buy rating on Rezolute Inc. (NASDAQ:RZLT) stock on October 23, citing strong confidence in the company’s lead candidate, ersodetug.

Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

White medicinal tablets. Photo by Kaboompics.com

Currently in Phase 3 trials for congenital hyperinsulinism (cHI), the drug has shown promise in addressing a significant unmet need through its novel insulin receptor-blocking mechanism. Zhong also highlighted Rezolute’s favorable competitive position, with ersodetug poised to gain substantial market share if approved. Additional opportunities in related conditions, such as tumor-induced hypoglycemia, further support a positive long-term outlook for the company.

Rezolute Inc. (NASDAQ:RZLT) is a biopharmaceutical company that develops therapies for rare and metabolic diseases. Its primary focus is on creating treatments for hyperinsulinism (HI), a rare genetic disorder that can cause dangerously low blood sugar, with its lead candidate being ersodetug.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.